Anthropic announced yesterday the launch of Claude Science, a new flagship product designed to support scientific research much like Claude Code supports software engineering. The announcement was made at an event for pharmaceutical executives, biotech founders, and researchers.
Claude Science operates autonomously from concise instructions
Like Claude Code, Claude Science can carry out complex tasks autonomously starting from high-level instructions. The system integrates specialized tools for computational biology and drug development, aiming to accelerate processes that traditionally take years of lab work.
Anthropic's focus on AI for science and rare diseases
Sponsored Protocol
With Claude Science, Anthropic doubles down on AI for science. The company will also use the product for its own internal research on drugs for rare and neglected diseases. This investment comes after the US lifted restrictions on some Anthropic models, as reported in the article US Lifts Export Curbs on Claude Fable 5 and Mythos 5, signaling growing trust in the company's capabilities.
AI already used for pharmaceutical discoveries
This is not the first time Anthropic's models have contributed to research. Recently, Claude Opus 4.7 helped a researcher identify a security flaw in Front Gate Tickets, demonstrating the versatility of AI. According to MIT Technology Review, Claude Science aims to reduce the time and cost of drug development, which currently exceeds 10 years and billions of dollars per drug.
Sponsored Protocol
Many startups are betting on AI to speed up drug discovery. Claude Science fits into this trend, offering predictive models that can simulate how molecules behave in the human body, eliminating ineffective compounds before they reach the experimental phase. However, it remains to be seen how these promises will translate into concrete results.
